NEWARK, N.J. \u2014 Novo Nordisk sued rival Eli Lilly in federal \u200bcourt on Tuesday, accusing the drugmaker of false advertising in claiming its weight-loss medicines outperform Novo’s drugs.<\/p>\n
The Danish company filed the lawsuit in U.S. District \u200cCourt in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham \u2060Act, through nationwide advertising campaigns for \u200bobesity drug Zepbound and diabetes treatment Mounjaro.<\/p>\n
Novo \u2060alleges Lilly compared the highest approved doses of its medicines with lower doses of \u200cNovo’s Wegovy and Ozempic while \u200comitting newer, higher-dose versions that Novo says deliver greater weight loss.<\/p>\n
“The ads \u2060are maliciously and deceptively false because Lilly knowingly \u2060cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines,” Novo wrote in its complaint.<\/p>\n
Eli Lilly could not be immediately reached for comment.<\/p>\n
Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and run a corrective advertising campaign. It added that \u200cit plans to seek a preliminary injunction if Lilly does \u200bnot voluntarily remove the ads.<\/p>\n
Novo is also seeking damages including Lilly’s profits that can be attributed to the ads.<\/p>\n
‘Inadequate disclaimer’ in ads<\/p>\n
Novo said it sent Lilly a cease-and-desist letter in April after the U.S. approved a 7.2 mg dose of Wegovy. Lilly did not respond to the letter, Novo’s general counsel John Kuckelman told Reuters, adding that the company instead inserted what he described as an inadequate disclaimer into the \u200badvertisements.<\/p>\n
Novo says the scale of Lilly’s campaign is massive. The ad campaign has been served up \u200cto consumers more \u200cthan 700 million \u2060times just since Lilly modified its ad after Novo’s letter in late April.<\/p>\n
Kuckelman said Lilly’s advertisements compare weight-loss results of about 50 pounds for Zepbound with about 33 pounds for Wegovy, even though no head-to-head trial has compared the highest approved doses of the medicines. \u200cHe said separate late-stage trials \u200bof the highest doses showed average weight loss \u200cof about 48 pounds \u2060for Zepbound and \u200b47 pounds for Wegovy.<\/p>\n
\n The Key Takeaways for this article were generated with the assistance of large language models and reviewed by our editorial team. The article, itself, is solely human-written.\n <\/p>\n","protected":false},"excerpt":{"rendered":"NEWARK, N.J. \u2014 Novo Nordisk sued rival Eli Lilly in federal \u200bcourt on Tuesday, accusing the drugmaker of…\n","protected":false},"author":2,"featured_media":133216,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[438,1298,6402,4007,393,6403,1343,428,33,38,272,6127,6404,135,2410,5423,6405,1646],"class_list":["post-133215","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-business","tag-cars","tag-classifieds","tag-finance","tag-health","tag-homes","tag-jobs","tag-law","tag-local","tag-news","tag-novo-nordisk","tag-radio","tag-salt-lake","tag-sports","tag-television","tag-traffic","tag-utah","tag-weather"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116962744575734286","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/133215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=133215"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/133215\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/133216"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=133215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=133215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=133215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}